Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SCRI-E2CAR_EGFRtv1

Phase 1Biologic

SSeattle Children's Hospital

SCRI-E2CAR_EGFRtv1 is one of 17 biologic programs targeting Sarcoma. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

16

Competitors

Pipeline

Status by Indication[3][1]

Indication

SarcomaActive, not recruiting

SarcomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

18 competitors in Sarcoma

#DrugCompanyPhaseTrials

Keytruda

Opdivo

Bristol-Myers Squibb

Tecentriq

Amtagvi

IIovance Biotherapeutics, Inc.

IC-Green

PProvepharm SAS

Talimogene Laherparepvec

NKTR-214

Bristol-Myers Squibb

Rapamune

PPrism Pharmaceuticals

Biological

NNational Environment Agency, Singapore

NEULASTA

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2040

Phase 1Active, not recruiting

Sarcoma

NCT05312411

Clinical

Trials by Indication[1]

Sarcoma1 trial

A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma

Active, not recruiting·SSeattle Children's Hospital·Phase 1·NCT05312411·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SCRI-E2CAR_EGFRtv1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SCRI-E2CAR_EGFRtv1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SCRI-E2CAR_EGFRtv1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seattle Children's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SSeattle Children's Hospital

Related News